Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy

NCT05039866 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.

NCT NCT05039866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05039866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy
Lead sponsor
Sangamo Therapeutics
Phase
Observational
Overall status
Active, not recruiting
Start date
August 16, 2021
Completion date
March 31, 2039
Enrollment
32 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease, fabry disease, cardiac variant